2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - New Orleans Theatre C
Treatment Considerations, Combination Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

77 Combination targeted therapy with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Long-term follow-up of safety, efficacy, and B-cell recovery

Gonca Ozcan, MD, Rahul Lakhotia I, MBBS2, Stefania Pittaluga Jr, MD3, James Phelan, PhD4, Da Wei Huang5, George W Wright6, Jagan Muppidi, MD, PhD7, Craig Thomas8, Michele Ceribelli9, Frances Tosto, MS10, Yandan Yang11, Weihong Xu12, Theresa Davies-Hill13, Svetlana Pack14, Amynah Pradhan15, Atekelt Tadese16, Anna Juanitez17, Elaine Jaffe, MD18, Mark Roschewski, MD19, Louis M Staudt, MD, PhD20, Wyndham Wilson21, Christopher Melani, MD22
1 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
2 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
3 Laboratory of Pathology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
4 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
5 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
6 Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
7 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
8 Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States
9 Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States
10 Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States
11 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
12 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
13 Laboratory of Pathology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
14 Laboratory of Pathology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
15 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
16 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
17 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
18 Laboratory of Pathology, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
19 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
20 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
21 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States
22 Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States

Background: Diffuse large B-cell lymphoma (DLBCL) is curable with chemoimmunotherapy; however, relapsed/refractory (R/R) patients (pts) have poor overall survival (OS). We developed ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) to simultaneously target multiple survival pathways in DLBCL and showed this regimen to be safe and able to induce durable remissions in pts with R/R DLBCL (Melani, NEJM, 2024). Long-term results and curative potential of ViPOR, however, remain uncertain as do the kinetics of B-cell recovery post-treatment. Herein, with over 6y of median follow-up, we report a long-term analysis of safety, efficacy, and B-cell recovery in pts with R/R DLBCL treated with ViPOR.

 

Methods: R/R DLBCL pts with adequate organ function were eligible. Six cycles of ViPOR q21d were given without maintenance as previously published (Melani, NEJM, 2024). Baseline CT, PET, BM, and tumor biopsies were performed with restaging CT after C1, 2, 4, and 6 and PET after C6. Surveillance CT scans with paired blood samples for lymphocyte subset analyses were then performed q3m x 1y, q4m x 1y, q6m x 1y, then q12m x 2y.

 

Results: 50 pts with R/R DLBCL were enrolled; including 13 with non-GCB DLBCL NOS, 12 with GCB DLBCL NOS, 17 with HGBCL-DH-BCL2, 3 with HGBCL-DH-BCL6, and 5 with THRLBCL. Seventeen (34%) pts had transformed DLBCL. Median (range) age was 61y (29-77) with IPI >3 in 34 (68%) pts. Median (range) prior lines of therapy were 3 (1-9) with prior CAR-T in 20 (40%) pts and 29 (58%) refractory pts per SCHOLAR-1 criteria. Fifteen (30%) pts received ViPOR as 2L therapy.

 

Overall response rate (ORR) and complete response (CR) rate were 54% and 38%, respectively, and remain unchanged as previously published. With a median (range) follow-up of 6.1y (4.8-8.2), 65% of all responses and 78% of CRs were ongoing at 5y. Median time-to-progression (TTP), progression-free survival (PFS), and OS were 4.38m, 4.38m, and 11.97m, respectively, with a 5y TTP, PFS, and OS of 37%, 29%, and 28%, respectively. Overall, 28 pts experienced disease relapse/progression and 35 pts died; 31 due to disease, 2 of complications following salvage allo-HSCT, and 2 of AML in ongoing CR 3y and 4.8y from study enrollment (both with 6+ prior lines of therapy including CAR-T). By histologic subtype, 5y TTP was 47% in HGBCL-DH-BCL2, 43% in non-GCB DLBCL NOS, 40% in THRLBCL, 33% @ 55m in HGBCL-DH-BCL6, and 17% in GCB DLBCL NOS. By line of therapy, 5y TTP was 60% when ViPOR was given as 2L compared to 28% as 3L+ therapy (P=0.02). In high-risk subsets, 5y TTP was 35% in post-CAR-T, 29% in transformed DLBCL, and 24% in refractory pts.

 

Median (range) absolute CD19+ B-cell count at baseline was 0 (0-332) cells/mcL with 51% (25/49) of pts having undetectable B-cells (0 cells/mcL) and 94% (46/49) of pts having low B-cells (<61 cells/mcL) prior to ViPOR initiation. Median (range) time to detectable (1-60 cells/mcL) or recovered B-cells (>60 cells/mcL) was 3m (1-49) and 31m (20-74), respectively. The rate of B-cell recovery at 1y, 3y, and 5y post-treatment was 0% (0/16), 50% (7/14), and 77% (10/13), respectively. Median (range) absolute CD3+ T-cell count at baseline was 432 (63-2283) cells/mcL with 63% (31/49) of pts having low T-cells (<714 cells/mcL) at baseline. No significant change in absolute CD3+ T-cell count was observed following ViPOR therapy (P=0.97) with a rate of T-cell recovery (>713 cells/mcL) at 1y, 3y, and 5y post-treatment of 44% (7/16), 79% (11/14), and 77% (10/13), respectively.

 

Conclusions: With over 6y of median follow-up, multi-targeted therapy with ViPOR induced durable remissions and likely cure in pts with R/R DLBCL, especially those with non-GCB DLBCL NOS and HGBCL-DH-BCL2. Durable remissions were also observed in high-risk subsets including refractory and post-CAR-T pts. Additionally, despite most pts having undetectable B-cells pre-treatment, many pts experienced full B-cell recovery post-treatment with no late infectious deaths observed. ViPOR treatment did not significantly impact T-cell counts and only 2 treatment-related malignancies occurred in 2 heavily pre-treated pts. Multicenter phase 2 testing of ViPOR in R/R non-GCB DLBCL and HGBCL-DH-BCL2 is currently ongoing to validate these single center findings. Furthermore, the efficacy of ViPOR as 2L therapy supports our future study of ViPOR-based treatment in untreated DLBCL.
Gonca Ozcan, MD: No relevant conflicts of interest to declare.